Researcher
Bart VAN WIJMEERSCH
- Keywords:Biomedical sciences (incl. biochemistry)
- Disciplines:Autoimmunity, Inflammation, Innate immunity, Transplantation immunology, Medical imaging and therapy not elsewhere classified, Neuroanatomy, Neurophysiology, Rehabilitation
Affiliations
- Rehabilitation Sciences (Faculty)
Member
From1 Sep 2018 → Today - Rehabilitation Research Center (Research group)
Member
From1 Sep 2018 → Today - Rehabilitation Sciences & Physiotherapy (Department)
Member
From1 Sep 2018 → Today - Biomedical Research Institute (Research institute)
Member
From1 Sep 2008 → Today - Immunology - Biochemistry (Research group)
Member
From1 Sep 2008 → 31 Aug 2018 - Physiology - Biochemistry - Immunology (Department)
Member
From1 Sep 2008 → 31 Aug 2018 - Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Sep 2008 → 31 Aug 2018 - Medical Basic Sciences (Division)
Member
From1 Sep 2008 → 30 Sep 2009
Projects
1 - 9 of 9
- Empirical development of a multimodal prognostication tool to guide treatment-strategy for Multiple SclerosisFrom1 Nov 2022 → TodayFunding: BOF - doctoral mandates
- Identification of multiple sclerosis-specific cytotoxic CD4 T cellsFrom1 Mar 2022 → 1 Mar 2023Funding: Industrial enterprises
- MACSiMiSE-BRAIN: Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And NeurodegenerationFrom1 Oct 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Short term changes in "Radiomic" features predict long-term treatment effectivenessFrom1 Sep 2019 → 31 Aug 2020Funding: Foreign foundations, funds with scientific view
- COGNITIVE-MOTOR INTERFERENCES DURING WALKING IN PERSONS WITH MULTIPLE SCLEROSIS: ASSESSMENT, REHABILITATION STRATEGIES AND NEURAL CORRELATESFrom1 Sep 2017 → 31 Aug 2021Funding: BOF - Doctoral projects
- Multiple sclerosis, a multidisciplinary approachFrom1 Jan 2015 → 31 Dec 2019Funding: FWO scientific research network
- T lymphocytes: from basic biology to immunotherapyFrom1 Oct 2012 → 31 Dec 2017Funding: IUAP-VII
- BOF NI project: A role for expanded CD4+CD28null T cells in patients with multiple sclerosis?From1 Jan 2012 → 31 Dec 2015Funding: BOF - Doctoral projects
- Multiple Sclerosis, a multidisciplinary appraochFrom1 Jan 2010 → 31 Dec 2014Funding: FWO scientific research network
Publications
111 - 120 of 160
- Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation(2017)
Authors: Marjan VANHEUSDEN, Bieke BROUX, Suzanne P. M. Welten, Liesbet PEETERS, Eleni Panagioti, Bart VAN WIJMEERSCH, Veerle SOMERS, Piet STINISSEN, Ramon Arens, Niels HELLINGS
Pages: 1 - 11 - Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study.(2017)
Authors: Lars Costers, Jeroen Gielen, Piet L. Eelen, Jeroen Van Schependom, Jorne Laton, Ann Van Remoortel, Ellen VANZEIR, Bart VAN WIJMEERSCH, Pierrette Seeldrayers, Marie-Claire Haelewyck, et al.
Pages: NP6 - NP6 - Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analyses(2017)
Authors: G. Comi, A. Boster, R. Alroughani, R. Berkovich, G. Izquierdo, D. Kantor, C. Laganke, V. Limmroth, R. Macdonell, T. Moreau, et al.
Pages: 492 - 492 - Teri-DYNAMIC: Exploring the impact of teriflunomide on immune cell population size, receptor repertoire, and function in patients with RRMS(2017)
Authors: Heinz Wiendl, Catharina C. Gross, Melanie Eschborn, Linda Weisser, Anita Posevitz-Fejfar, Andreas Schulte-Mecklenbeck, Bart VAN WIJMEERSCH, Raymond Hupperts, Sandrine Brette, Timothy J. Turner, et al.
Pages: 144 - 144 - Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study(2017)
Authors: Lars Costers, Jeroen Gielen, Piet L. Eelen, Jeroen van Schependom, Jorne Laton, Ann Van Remoortel, Ellen VANZEIR, Bart VAN WIJMEERSCH, Pierrette Seeldrayers, Marie-Claire Haelewyck, et al.
Pages: 33 - 40 - Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients(2016)
Authors: Nele CLAES, Judith FRAUSSEN, Marjan VANHEUSDEN, Niels HELLINGS, Piet STINISSEN, Bart VAN WIJMEERSCH, Raymond Hupperts, Veerle SOMERS
Pages: 4576 - 4583 - B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses(2016)
Authors: Judith FRAUSSEN, Nele CLAES, Bart VAN WIJMEERSCH, Jack VAN HORSSEN, Piet STINISSEN, Raymond Hupperts, Veerle SOMERS
Pages: 124 - 132 - Brain atrophy by automated MRI reading in long-term natalizumab treated patients: Real world data suggests brain atrophy rates in range of healthy individuals(2016)
Authors: Dana Horakova, T. Uher, M. Vaneckova, J. Krasensky, Z. Seidl, V. van Pesch, A. Lysandropoulos, Bart VAN WIJMEERSCH, A. Ribbens, W. van Hecke, et al.
Pages: 866 - 867 - Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment(2016)
Authors: R. Bermel, G. Comi, J. -P. Eralinna, T. P. Leist, R. Nicholas, C. Oreja-Guevara, A. Siva, Bart VAN WIJMEERSCH, H. Wiendl, C. Bernasconi, et al.
Pages: 615 - 616 - Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)(2016)
Authors: C. Oreja-Guevara, R. Alroughani, D. Brassat, A. N. Boyko, P. McCombe, B. Steingo, Bart VAN WIJMEERSCH, D. H. Margolin, K. Thangavelu, C. E. Rodriguez, et al.
Pages: 648 - 649